Related Experiment Video
Updated: Aug 8, 2026
14:55
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Extrapyramidal symptoms with selective serotonin reuptake inhibitors
1Peter Hodgkinson Centre, County Hospital, Lincoln.
The British Journal of Psychiatry : the Journal of Mental Science
|December 1, 1994
Summary
Selective serotonin reuptake inhibitors (SSRIs) may cause extrapyramidal symptoms in some patients. Research suggests a link between the serotonergic and dopaminergic systems may be responsible.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Case reports indicate selective serotonin reuptake inhibitors (SSRIs) may induce extrapyramidal symptoms.
- Extrapyramidal symptoms are a known potential side effect of certain medications.
Purpose of the Study:
- To investigate the association between SSRIs and extrapyramidal symptoms.
- To explore the potential mechanisms underlying SSRI-induced extrapyramidal symptoms.
Main Methods:
- Conducted computerized literature searches for reports on SSRIs and extrapyramidal symptoms.
- Performed manual searches to identify studies detailing the mechanisms of these symptoms.
Main Results:
- A limited number of reports were found implicating SSRIs in extrapyramidal symptoms.
- Evidence suggests a connection between SSRI use and the occurrence of these symptoms in some individuals.
Conclusions:
- Preclinical and clinical evidence points to the interaction between serotonergic and dopaminergic neurotransmitter systems.
- This neurochemical interaction is proposed as a potential mechanism for SSRI-induced extrapyramidal symptoms.
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...